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Nanosized sustained-release drug depots fabricated using modified tri-axial electrospinning Guang 
Introduction
Nanosized drug depots, in which a drug reservoir is surrounded by pharmaceutical excipients, have attracted much attention in the biomedical field recently [1] [2] [3] [4] [5] [6] . They have been explored for drug delivery through a variety of administration routes (such as oral, injected, inhaled, and implanted) and also as stents in tissue engineering [7] [8] [9] [10] [11] . Two trends are obvious with this type of biomaterials.
One is that almost all the depots take the form of nanoparticles, microspheres or microemulsions [12] [13] [14] . Another is that the fabrication methods are mainly "bottom-up" approaches, including chemical synthesis, molecular self-assembly and emulsion methods; these are often time-consuming and very difficult to perform on a large scale [15] [16] [17] [18] . New approaches for creating this kind of nanostructure, particularly "top-down" methods that can be scaled up easily, would offer great benefit to the fields of biomaterials and pharmaceutics.
One such route is the electrospinning technology, which uses electrical energy to produce nanoscale fiber composites from solutions of a polymer and functional component. After rapid development in the last two decades, the most exciting new work on electrospun fibers falls in two areas. The first is scale-up, with production on an industrial scale now possible. This has mainly been investigated in the context of monolithic fibers with one or two functional ingredients/nanoparticles distributed homogeneously in the filament-forming polymer matrix [19] [20] [21] [22] . The second is the creation of more complex nanostructures (such as core-shell and Janus systems, and combinations thereof) in order to yield materials with improved functional performance [23] [24] [25] [26] . In the biomedical field, if a drug reservoir could be formed as the core of electrospun core-shell fibers, then new fiber-based nanoscale drug depots could be created, such as an electrospun suture [27] . These would differ significantly from the nanoparticle-based depots which have mainly been explored to date. In the cases of coaxial and tri-axial electrospinning, it is possible to run these with only one of the working fluids being electrospinnable alone [28, 29] . In standard coaxial electrospinning, the sheath fluid must be electrospinnable to support the electrospinning process and the formation of core-shell structures [30] . However, a modified coaxial electrospinning process, characterized by the utilization of un-spinnable liquids as the sheath working fluids can also be implemented [29, 31] .
Similarly, traditional tri-axial electrospinning always uses an electrospinnable outer fluid [32] [33] [34] [35] [36] [37] [38] [39] [40] . A modified tri-axial process focused on the exploitation of un-spinnable liquids has also been reported [28] . These might comprise solvents, small molecule solutions, emulsions and suspensions, and should lead to a range of novel structures.
Thus, it can be hypothesized that these technologies can be exploited to create drug-loaded nanofibers containing drug reservoirs even though the drug itself has no filament-forming properties.
A wide variety of raw materials have been investigated as the shell for encapsulating a core drug reservoir. These materials include the traditional pharmaceutical excipients approved by the FDA such as natural polymers, a range of synthetic polymers, and phospholipids, but also more exotic systems including hydrogels and even inorganic material such as TiO 2 [41] [42] [43] [44] . Naturally-occurring polymers remain a key focus of research interest because of their abundant supply and relatively environmentally-friendly preparation routes. This is reflected in the frequent use of cellulose and its derivatives not only in the scientific literature but also in the food and pharmaceutical industries [45, 46] . In particular, cellulose acetate (CA), the acetate ester of cellulose, has broad applications -for instance in the coatings of pharmaceutical and food products, and as film in photography [47] . CA has been also frequently been utilized as the filament-forming polymer for creating drug-loaded nanofibers through single-fluid electrospinning spinning [48] . However, the direct electrospinning of CA is non-facile because the need to use volatile solvents in this process causes frequent clogging of the spinneret [31] . Furthermore, monolithic drug loaded CA nanofibers tend to exhibit an undesirable initial burst release [49, 50] , which inhibits their potential as sustained-release biomaterials.
In this work, with the phytochemical ferulic acid (FA) as a model drug, we explore the preparation of CA-based nanoscale drug depots using a modified tri-axial electrospinning process. As a control, monolithic drug-CA fibers were produced using a modified coaxial process. The fiber morphologies, structures, functional performance, and the distribution and physical form of the drug in the formulations were compared in detail.
Experimental section

Materials
Ferulic acid (FA; purity> 98%) was purchased from the Yunnan Yunyao Lab Co., Ltd.
(Kunming, China). CA (M w =100,000 Da) was obtained from Acros Organics (Geel, Belgium). Methylene blue, methylene orange, N,N-dimethylacetamide (DMAc), anhydrous ethanol and acetone were obtained from the Shanghai SSS Reagent Co., Ltd. (Shanghai, China). All other chemicals were analytical grade commercial products. Freshly double distilled water was used where required.
Electrospinning
Three kinds of electrospinning processes (traditional coaxial, modified coaxial and modified tri-axial) were explored for preparing fibers. Table 1 . To aid optimization of the experimental conditions, 2 µg/mL of methylene blue and methylene orange were added to the inner and middle working fluids, respectively.
Table1
Characterization
Morphology
The morphology of the fibers and their cross-sections were probed using a Quanta FEG450 field emission scanning electron microscope (SEM; FEI Corporation, Hillsboro, OR, USA). Before examination, samples were sputter-coated with platinum under argon. A polarized optical microscope (XP-700, Chang-Fang Optical Instrument Co., Ltd., Shanghai, China) was used to study the raw drug powders and CA particles. The fiber diameters were estimated from SEM images using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). Samples of fibers for cross-section analysis were prepared immersion in liquid nitrogen for 20 min, after which they were manually broken.
Physical form
X-ray diffraction patterns (XRD) were recorded on a Bruker AXS diffractometer (Bruker, Karlsruhe, Germany). Fourier transform infrared (FTIR) analysis was carried out on a Spectrum 100 FTIR Spectrometer (Perkin Elmer, Billerica, MA, USA). For the latter, samples were prepared using the KBr disc method.
In vitro drug release
FA has a maximum absorbance at λ max = 322 nm [51] , and was quantified on a Lambda 950 UV/vis/NIR spectrophotometer (Perkin Elmer, Billerica, MA, USA) following construction of a calibration curve. The in vitro drug release profiles were measured according to the Chinese Pharmacopoeia (paddle method, 2015 Ed.) using a dissolution apparatus with six cells (RCZ-8A, Tianjin University Radio Factory, Tianjin, China). 40 mg of FA powder (particle size < 20 µm) or 0.2 g of the F2 and F3 fibers (containing the equivalent amount of FA) were placed in 900 mL of phosphate buffered saline (PBS, pH 7.0, 0.1M) at 37 ± 1 ºC, with a 50 rpm rotation speed. All experiments were performed under sink conditions. At pre-determined time points, 5.0 mL of the dissolution liquid was removed for analysis. 5.0 mL of pre-heated PBS was then added to the cells to maintain a constant volume. All experiments were repeated six times, and the results are reported as mean ± S.D.
Statistical analysis
The experimental data are presented as mean ± SD. The results from the in vitro dissolution tests were analyzed using one-way ANOVA. The threshold significance level was set at 0.05. Thus, p (probability) values lower than 0.05 were considered statistically significant.
Results and discussion
Modified tri-axial electrospinning
Electrospinning is commonly considered to be easy, low-cost and straightforward, giving products that have large surface areas and high porosity. However, the most fascinating aspect of this technique in the authors' view is that complicated nanostructures can easily be created in a "top-down" manner through a single step in double-or multiple-fluid spinning, allowing systems to be accessed which are difficult or even impossible to achieve from "bottom-up" synthesis processes [52] .
The implementation of double-or multiple-fluid processes is similar to the one-fluid process (Fig. 1a) , except that more complex spinnerets are required. The introduction of un-spinnable fluids into the process can greatly expand the range of novel functional nanomaterials which can be produced [28] . There are only slightly over 100 polymers which have filament-forming properties in electrospinning, and even these often can only be processed in a very narrow concentration window [53] . Our previous report of modified tri-axial spinning used a pure solvent as the outer fluid, a spinnable Eudragit solution in the center, and an unspinnable drug/phospholipid core, with the aim of generating a colon-targeted delivery system [28] . This comprised a useful proof-of-concept but there are myriad further opportunities to explore, and we expand significantly on this previous work here.
Fig. 1.
Building on our previous investigations [28, 29, 32] , we sought to use tri-axial electrospinning to prepare novel CA-based depot structures in this work (Fig. 1b) . In addition to the tri-layer concentric spinneret, a polymer-coated concentric spinneret was applied for carrying out coaxial spinning. Digital images of the concentric and tri-layer spinneret nozzles are shown in Fig. 2a1 to a4 . The concentric spinneret is coated with polyvinyl chloride (PVC), an antistatic material. It is able to effectively prevent electrical energy loss to the surroundings. It also helps to prevent interactions between the spinneret and working fluids, and reduces the clogging of the spinneret which can occur as a result of the build-up of solid material on it [54] .
The PVC-coated concentric spinneret was found to be rapidly clogged when a traditional coaxial electrospinning experiment was conducted with a 12% w/v CA solution as the shell and a pure FA solution for the core working fluid (Fig. 2b) . Thus, the collection of the F1 fibers was abandoned. However, using a co-dissolving solution containing both CA and FA as the core fluid, and a solvent sheath fluid, a modified coaxial process could be implemented to create monolithic FA-loaded CA nanofibers (F2) using the same spinneret (Fig. 2c) . The latter processes run smoothly and continuously because of the "lubrication effect" of the sheath solvent mixture.
The presence of a surrounding solvent at the exit of spinneret replaces the interfaces between the viscous polymer solution and the atmosphere with a solvent/atmosphere interfaces, which can effectively prevent premature drying and clinging of the working polymer fluid. Thus, with the two-needle spinneret, only monolithic fibers can be generated.
The connections of the tri-layer concentric spinneret to the syringe pumps and the power supply are shown in Fig. 2d . A typical working process under the optimized experimental parameters is depicted in Fig. 2e . A Taylor cone can be seen on the spinneret; this ejects a straight fluid jet, which is followed by numerous gradually enlarged coiled circles. The bottom-right inset of Fig. 2e gives a clear image of the compound Taylor cone with three different fluid layers, as indicated by the color-markers methylene orange and methylene blue. The implementation of a modified tri-axial process could thus lead to the production of core-shell structures, which was not possible through a standard co-axial process owing to the need to have a lubricating shell solvent to facilitate the process. 
Fiber morphology
Both the fibers from the modified coaxial process, (F2; Fig. 3a1 and a2) and those from the modified tri-axial process (F3; Fig. 3b1 and b2) 
Physical form and component compatibility
It is commonly the case that electrospun fibers with a drug homogeneously distributed in the polymer matrix are amorphous solid dispersions, which are beneficial for the dissolution of poorly water-soluble drugs [19, 51] . XRD patterns of the raw materials (CA and FA) and their electrospun products are shown in Fig. 5a .
The raw CA material is amorphous, as reflected by the broad humps in its XRD pattern and also the appearance of its particles under the microscope (Fig. 5b) . In contrast, the raw FA particles are crystalline, with many sharp reflections in the XRD pattern. This is verified by the FA particles showing polychromic properties under polarized light (Fig. 5c ).
The F2 fibers from the modified coaxial process have an XRD pattern with no characteristic reflections of crystalline FA, indicating production of an amorphous material. However, it is clear that there are still some FA reflections in the pattern of F3 (Fig. 5a ). This can be ascribed to the use of a pure drug solution as the core:
without the steric hindrance provided by the presence of a polymer, the FA molecules are able to re-crystallize during the process of solvent evaporation.
Fig. 5.
To explore the possibility of any secondary interactions existing between the components in the composite fibers, FTIR spectra were obtained, and are given in Fig.   6a . The molecular formulae of CA and FA are exhibited in Fig. 6b . Both CA and FA have hydroxyl and carboxylate groups and thus can both donate and accept H-bonds.
The CA spectrum contains a characteristic -C=O absorbance peak at 1727 cm -1 , while FA has -C=O absorbance peaks at 1691, 1667 and 1619 cm -1 . Fig. 6b shows that FA molecules can potentially form two different dimers, and the presence of these in the pure drug is believed to be the reason for the three different carboxylate vibrations.
These characteristic peaks have disappeared in the spectrum of F2 but can still be discerned in that of F3. In addition, the numerous sharp peaks in the fingerprint region of raw FA are absent in the F2 spectrum but can still be observed with F3. These observations suggest that the major secondary interactions present in the fibers are likely to be different. In F2, all the FA molecules were homogeneously distributed throughout the CA matrix. These FA molecules formed hydrogen bonds with the -OH or -C=O groups of CA, which hinders the formation of FA dimers and crystal lattices.
In comparison, in the case of F3 most of the FA molecules were centralized in the core, and given the lack of polymer here the formation of FA dimers and a crystal lattice could occur. 
In vitro drug release
FA is a typical poorly water-soluble active pharmaceutical ingredient, with a saturation solubility of 0.00583% (w/w) in water at 37 ºC [51] . Its dissolution rate is closely related to its particle size. In this work, the complete dissolution of 40 mg of FA with a particle size smaller than 20 µm took around 12 h in PBS (Fig. 7a) , with 75.8 ± 5.4% of the drug freed into the bulk dissolution media in the first 4 h (Fig. 7b) .
As a result of the insolubility of CA, the F2 fibers provided a sustained release profile over a time period of around 96 h (Fig. 7a) . However, a significant initial burst release (27.4 ± 5.7%) within the first hour is clear (Fig. 7b) , as a result of a significant proportion of the drug molecules in the fibers being close to the surface and thus able to diffuse into the release medium. This burst is even more pronounced than the raw FA (23.7 ± 6.17%). After 48 h, 88.4 ± 6.8% of the incorporated FA in F2 was released.
This left a long tailing-off period, with a further 48 h required to release only 7.1% of the remaining FA.
The F3 fibers release profile is also given in Fig. 7a . F3 released only 3.7 ± 2.4%
of the encapsulated FA in the first hour of the experiment, and 11.9 ± 5.1% after 2 h (Fig. 7b) . After 36 h, 93.7 ± 6.4% of the FA incorporated was freed into the dissolution medium (Fig. 7a) . Although both F2 and F3 were able to provide a more sustained release profile than raw FA powder (found in commercial tablets), the F3 fibers showed even better functional performance than F2. The F3 depots had no initial burst release effect, which often results in a higher blood drug concentration than the maximum safe concentration (MSC) [55] . Meanwhile, the F3 depots had less leveling-off release during the final stages of release, which often leads to a lower blood drug concentration than the minimum effective concentration (MEC) [56] .
Fitting release models to the in vitro release data of F3 from 0 to 36 hours shows that FA was released in an almost zero-order manner. A linear equation between the drug release percentage (Q) and the release time (T) was calculated: Q=2.54T+8.57, with a correlation coefficient (R) of 0.9868 (Fig. 7c) . 
Drug release mechanism
To further explore the drug release mechanisms of F2 and F3, samples were removed from the dissolution cells and lyophilized at the end of the experiments.
SEM images of the cross-sections of these samples, together with schematics of the drug distribution in the fibers, are exhibited in Fig. 8 . F2 has a uniform cross-section (Fig. 8a) , while F3 displays a loose, collapsed, structure in the center of the CA shell ( Fig. 8b) , as a result of the exhaustion of the core FA crystals.
CA is insoluble in water, and in the pharmaceutical industry is often exploited for sustained release membrane coatings or osmotic pumps [57] . Drug release from CA-based drug delivery systems (DDSs) is reported to be controlled by a typical Fickian diffusion mechanism. The Peppas equation Q = kt n can be utilized to gain more insight here. Q is the drug release percentage, t is the time, k is a constant reflecting the structural and geometric characteristics of the DDS, and n is an exponent indicating the drug release mechanism [58] . However, it is more likely that the Peppas model is not really applicable here, since there is not a uniform distribution of the drug throughout the matrix (see Fig. 8c ).
During the drug dissolution process, the insoluble CA will not degrade or abrade, and thus erosion should not occur. The composite F2 fibers do have the drug homogeneously distributed throughout the CA matrix however (Fig. 8c) , and thus the Peppas equation could successfully model the release from these fibers.
Fig. 8.
Although the drug FA molecules have re-crystallized in the core of F3 (Fig. 8c) , the drug release process is approximately zero-order, with no initial burst release and a very small tailing-off effect. This is thought to be because transport of FA from the central depots to the outer dissolution medium must involve three successive steps.
First, water molecules must permeate to the cores of the fibers. Second, FA molecules must dissolve from the solid state into solution, and finally the free FA molecules must migrate through the CA shell to the dissolution medium. It is hypothesized that a saturated FA solution could form in the core, and since the diffusion distance to the release medium is constant (i.e. the thickness of the CA shell, T shell ), close to zero-order release ensues. In contrast, in the composite F2 system, the drug at the exterior of the fiber monoliths would exit first, and thus as time passes the diffusion distances will gradually increase. This leads to an accelerated burst of release at the start of the experiment, and also to the tailing off in its final stages.
We believe that the new results reported here could leads to a series of novel biomaterials aiming to provide controlled release profiles. For instance: 1) in the shell, soluble porogenic additives (such poly(ethylene glycol) or poly(vinylpyrrolidone)) could be used to regulate the drug release behavior, as is currently the case in some particle-based drug depots [59] ; 2) the approach could be extended to achieve the sustained release of soluble drugs (a major challenge in pharmaceutics); 3) drug delivery systems with more complicated drug release profiles could be achieved, e.g.
multiple-phase release of a drug using a pure drug exterior compartment; 4) combined therapies with temporally sequential drug release characteristics could be explored; 5)
an extremely wide range of un-spinnable fluids including dilute polymer solutions [60] , surfactant or electrolyte solutions could be explored as the outer fluid in modified tri-axial processes, in order to create numerous nanoscale biomaterials with complicated nanostructures.
Conclusions
In this work, a modified tri-axial electrospinning process was successfully developed 
